Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: A device for grinding a continuously cast product, in particular a slab (11), a billet or a block. The Device has at least one rotationally operated abrasive disk (10), which is attached to a grinding head (15). At least one high-pressure air nozzle (14) is arranged on the grinding head (15). The high-pressure air nozzle blows the continuously cast product free of particles adhering to or lying on the continuously cast product prior to grinding.

Abstract: Described herein are coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a solvate and additionally optionally as a hydrate, including crystalline forms, and methods of preparing the (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-teirahydroquinoline-5-carboxylate optionally as a coformer salts.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.

Abstract: Described herein are coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a solvate and additionally optionally as a hydrate, including crystalline forms, and methods of preparing the (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a coformer salts.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: A friction stir welding tool with a base, a rotating friction stir slug mounted in the said base and at least one guide member connected to the said base, the welding tool being adapted to move from upstream to downstream; a welding tool having at least one displacement member of the guide member relative to the said base between at least one guiding position in which the guide member extends in a scout area located downstream and facing the friction stir slug and at least one retracted position in which the guide member is offset from the said scout area.

Abstract: Provided are methods for treating skin disorders comprising topically applying a highly stable pharmaceutical composition comprising bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof.

Abstract: Described herein are coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a solvate and additionally optionally as a hydrate, including crystalline forms, and methods of preparing the (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1, 2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate optionally as a coformer salts.

Abstract: The present invention relates to improved microparticles comprising a somatostatin analog, a process of making said microparticles and to pharmaceutical compositions comprising the same.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof

Abstract: A pharmaceutical composition for parenteral administration of a somatostatin analog salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.

Abstract: A friction stir welding tool with a base, a rotating friction stir slug mounted in the said base and at least one guide member connected to the said base, the welding tool being adapted to move from upstream to downstream; a welding tool having at least one displacement member of the guide member relative to the said base between at least one guiding position in which the guide member extends in a scout area located downstream and facing the friction stir slug and at least one retracted position in which the guide member is offset from the said scout area.

Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.

Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.

Abstract: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Dalton's, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.

Abstract: Microparticles consisting of (a) a matrix with a mixture of (a1)) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.

Abstract: Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.